HUTCHMED begins global Phase Ia trial of HMPL-A830 in solid tumors after GSK licensing deal
HUTCHMED dosed its first patient in a Phase Ia study of KRAS-EGFR antibody conjugate HMPL-A830, following a licensing agreement with a GSK subsidiary covering territories outside Greater China.
The week's main development for HUTCHMED centers on its new antibody-targeted therapy conjugate candidate.
- HMPL-A830, a Phase Ia trial in patients with unresectable, advanced or metastatic solid tumors, began dosing, with the first patient receiving the first dose in China on September 24, 20261. The study is a first-in-human, multicenter, open-label Phase I trial designed to evaluate safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy, with the current Phase Ia portion aimed at determining the maximum tolerated dose and recommended dose for expansion1. The trial is listed under NCT07718581, according to the filing.
- On September 3, 2026, HUTCHMED Limited, described in the filing as a subsidiary of the company, signed a licensing deal with a subsidiary of GSK plc covering development and commercialization rights to HMPL-A830 in worldwide territories excluding Mainland China, Hong Kong, Macau and Taiwan1. Under the arrangement, HUTCHMED Limited remains responsible for the global Phase I development program, while the GSK subsidiary will handle all later-stage clinical development and commercialization outside Greater China1. The deal remains subject to customary closing conditions, including completion of any antitrust regulatory reviews1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.